Chlorthalidone

Evidence Level: L5

Predicted Indications: 9

Chlorthalidone

Pharmacist Assessment Report

Chlorthalidone: thiazide-like diuretic → primary hereditary glaucoma

One-Sentence Summary

Chlorthalidone is a thiazide-like diuretic that is marketed in Australia as a single-ingredient tablet. The TxGNN model predicts it may be effective for primary hereditary glaucoma, with a score of 0.9992. There are no clinical trials and no publications on this disease in the data compiled for this report, so the prediction rests on the model alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	primary hereditary glaucoma
TxGNN Prediction Score	0.9992
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data are not available in the data compiled for this report. Chlorthalidone is a thiazide-like diuretic that acts on ion transport and fluid balance, and it is established as an antihypertensive.

A diuretic could in theory lower intraocular pressure through effects on ion transport or fluid balance. This is speculative and is not supported by any data provided. Primary hereditary glaucoma is largely driven by genetic defects in aqueous outflow, so a systemic diuretic mechanism is not a clear fit. The high score should be treated as a model signal that needs verification, not as evidence of benefit.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 13500M	Hygroton 25	Tablet 25 mg	Not recorded in the local data

Safety Considerations

Disease associations of concern: The data compiled for this report list conditions in which chlorthalidone is flagged as contraindicated or to be used with caution. These come from model-source relations, not from label text. They include:
- Kidney and liver: kidney disease, liver failure, anuria
- Metabolic: gout, hyperuricaemia, type 2 diabetes mellitus, hypercalcaemia, potassium deficiency
- Cardiovascular: myocardial infarction, sudden cardiac arrest
- Other: pancreatitis, peptic ulcer disease, systemic lupus erythematosus, asthma, psoriasis, epilepsy
Drug interactions: 210 interactions were recorded. Major-level interactions include cisapride and dolasetron. Many moderate-level interactions involve glucose-lowering agents (metformin, acarbose, alogliptin, albiglutide), corticosteroids (hydrocortisone, dexamethasone, triamcinolone, beclomethasone), amphotericin B, bupropion, morphine, and the proton pump inhibitors omeprazole and rabeprazole. Minor interactions include atropine, hyoscyamine and doxycycline.

Please refer to the TGA-approved Product Information (PI) for authoritative warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction for primary hereditary glaucoma has no supporting trials or publications, and the proposed mechanism is speculative and a poor fit for a genetically driven outflow disorder. Evidence is L5 (model prediction only).

To proceed, the following is needed:

Mechanism of action data for chlorthalidone and a plausible link to intraocular pressure regulation
Preclinical or clinical studies that directly address primary hereditary glaucoma
Safety information from the TGA Product Information, including a review of the ocular and systemic risks of a diuretic in this population
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.